α ace2 ak Search Results


α ace2 ak  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology α ace2 ak
a , Quantification of VSV(luc)ΔG*SARS-CoV-2-S entry by measuring luciferase activity in HEK293T cells transiently expressing the indicated IFITM proteins. Bars in all panels show results of three independent experiments (mean value, ±SEM). b , Calu-3 cells treated with non-targeting (CTRL) or IFITM1, 2 or 3 siRNAs or a combination of the three and infected with VSV(luc)ΔG*SARS-CoV-2-S particles. c , Quantification of RNA containing N gene sequences by qRT-PCR in the supernatant of HEK293T cells transiently expressing <t>ACE2</t> alone or together with the indicated IFITM proteins 48 h post-infection with SARS-CoV-2 (MOI 0.05). d , RNA containing N gene sequences levels in the supernatant of Calu-3 cells, collected 48 h post-infection with SARS-CoV-2 (MOI 0.05). Cells were transfected with control (CTRL) or IFITM1, 2 and/or 3 targeting siRNA or a combination of the three and either treated with IFN-β or left untreated as indicated. e , Cytopathic effects in Vero cells infected with serial dilutions of Calu-3 supernatants from . Cells were stained with crystal violet.
α Ace2 Ak, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α ace2 ak/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
α ace2 ak - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
α-ifitm2  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc α-ifitm2
a , Quantification of VSV(luc)ΔG*SARS-CoV-2-S entry by measuring luciferase activity in HEK293T cells transiently expressing the indicated IFITM proteins. Bars in all panels show results of three independent experiments (mean value, ±SEM). b , Calu-3 cells treated with non-targeting (CTRL) or IFITM1, 2 or 3 siRNAs or a combination of the three and infected with VSV(luc)ΔG*SARS-CoV-2-S particles. c , Quantification of RNA containing N gene sequences by qRT-PCR in the supernatant of HEK293T cells transiently expressing <t>ACE2</t> alone or together with the indicated IFITM proteins 48 h post-infection with SARS-CoV-2 (MOI 0.05). d , RNA containing N gene sequences levels in the supernatant of Calu-3 cells, collected 48 h post-infection with SARS-CoV-2 (MOI 0.05). Cells were transfected with control (CTRL) or IFITM1, 2 and/or 3 targeting siRNA or a combination of the three and either treated with IFN-β or left untreated as indicated. e , Cytopathic effects in Vero cells infected with serial dilutions of Calu-3 supernatants from . Cells were stained with crystal violet.
α Ifitm2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α-ifitm2/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
α-ifitm2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
α ifitm3 proteintech 11714 1 ap  (Proteintech)
95
Proteintech α ifitm3 proteintech 11714 1 ap
a , Quantification of VSV(luc)ΔG*SARS-CoV-2-S entry by measuring luciferase activity in HEK293T cells transiently expressing the indicated IFITM proteins. Bars in all panels show results of three independent experiments (mean value, ±SEM). b , Calu-3 cells treated with non-targeting (CTRL) or IFITM1, 2 or 3 siRNAs or a combination of the three and infected with VSV(luc)ΔG*SARS-CoV-2-S particles. c , Quantification of RNA containing N gene sequences by qRT-PCR in the supernatant of HEK293T cells transiently expressing <t>ACE2</t> alone or together with the indicated IFITM proteins 48 h post-infection with SARS-CoV-2 (MOI 0.05). d , RNA containing N gene sequences levels in the supernatant of Calu-3 cells, collected 48 h post-infection with SARS-CoV-2 (MOI 0.05). Cells were transfected with control (CTRL) or IFITM1, 2 and/or 3 targeting siRNA or a combination of the three and either treated with IFN-β or left untreated as indicated. e , Cytopathic effects in Vero cells infected with serial dilutions of Calu-3 supernatants from . Cells were stained with crystal violet.
α Ifitm3 Proteintech 11714 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α ifitm3 proteintech 11714 1 ap/product/Proteintech
Average 95 stars, based on 1 article reviews
α ifitm3 proteintech 11714 1 ap - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
α ifitm1 cell signaling  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc α ifitm1 cell signaling
a , Quantification of VSV(luc)ΔG*SARS-CoV-2-S entry by measuring luciferase activity in HEK293T cells transiently expressing the indicated IFITM proteins. Bars in all panels show results of three independent experiments (mean value, ±SEM). b , Calu-3 cells treated with non-targeting (CTRL) or IFITM1, 2 or 3 siRNAs or a combination of the three and infected with VSV(luc)ΔG*SARS-CoV-2-S particles. c , Quantification of RNA containing N gene sequences by qRT-PCR in the supernatant of HEK293T cells transiently expressing <t>ACE2</t> alone or together with the indicated IFITM proteins 48 h post-infection with SARS-CoV-2 (MOI 0.05). d , RNA containing N gene sequences levels in the supernatant of Calu-3 cells, collected 48 h post-infection with SARS-CoV-2 (MOI 0.05). Cells were transfected with control (CTRL) or IFITM1, 2 and/or 3 targeting siRNA or a combination of the three and either treated with IFN-β or left untreated as indicated. e , Cytopathic effects in Vero cells infected with serial dilutions of Calu-3 supernatants from . Cells were stained with crystal violet.
α Ifitm1 Cell Signaling, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α ifitm1 cell signaling/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
α ifitm1 cell signaling - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


a , Quantification of VSV(luc)ΔG*SARS-CoV-2-S entry by measuring luciferase activity in HEK293T cells transiently expressing the indicated IFITM proteins. Bars in all panels show results of three independent experiments (mean value, ±SEM). b , Calu-3 cells treated with non-targeting (CTRL) or IFITM1, 2 or 3 siRNAs or a combination of the three and infected with VSV(luc)ΔG*SARS-CoV-2-S particles. c , Quantification of RNA containing N gene sequences by qRT-PCR in the supernatant of HEK293T cells transiently expressing ACE2 alone or together with the indicated IFITM proteins 48 h post-infection with SARS-CoV-2 (MOI 0.05). d , RNA containing N gene sequences levels in the supernatant of Calu-3 cells, collected 48 h post-infection with SARS-CoV-2 (MOI 0.05). Cells were transfected with control (CTRL) or IFITM1, 2 and/or 3 targeting siRNA or a combination of the three and either treated with IFN-β or left untreated as indicated. e , Cytopathic effects in Vero cells infected with serial dilutions of Calu-3 supernatants from . Cells were stained with crystal violet.

Journal: bioRxiv

Article Title: IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition

doi: 10.1101/2020.08.18.255935

Figure Lengend Snippet: a , Quantification of VSV(luc)ΔG*SARS-CoV-2-S entry by measuring luciferase activity in HEK293T cells transiently expressing the indicated IFITM proteins. Bars in all panels show results of three independent experiments (mean value, ±SEM). b , Calu-3 cells treated with non-targeting (CTRL) or IFITM1, 2 or 3 siRNAs or a combination of the three and infected with VSV(luc)ΔG*SARS-CoV-2-S particles. c , Quantification of RNA containing N gene sequences by qRT-PCR in the supernatant of HEK293T cells transiently expressing ACE2 alone or together with the indicated IFITM proteins 48 h post-infection with SARS-CoV-2 (MOI 0.05). d , RNA containing N gene sequences levels in the supernatant of Calu-3 cells, collected 48 h post-infection with SARS-CoV-2 (MOI 0.05). Cells were transfected with control (CTRL) or IFITM1, 2 and/or 3 targeting siRNA or a combination of the three and either treated with IFN-β or left untreated as indicated. e , Cytopathic effects in Vero cells infected with serial dilutions of Calu-3 supernatants from . Cells were stained with crystal violet.

Article Snippet: Calu-3 cells were seeded in 48-well format (peptides assays), or in 24-well format (antibodies assay), 24h later cells were treated with increasing concentrations (20 and 80µg/ml) of IFITMs derived peptides (human IFITM2 long: EEQEVAMLGVPHNPAPPMSTVIH, human IFITM2 short: QEVAMLGVPHNAPPMST-VIH, mouse IFITM2 long: EEYGVTELGEPSNSAVVRTTVIN, human IFITM3 long: EEHEVAVLGAPHNPAPPTSTVIH, scrambled IFITM2: EGESGVTTATVEVVIERNN-LPY) or blocking antibodies (15 and 30 µg/ml) (α-ACE2 AK (AC18Z), Santa Cruz Biotechnology sc-73668; α-IFITM1 Cell Signaling 13126 S, α-IFITM2 Cell Signaling 13530S, α-IFITM3 Proteintech 11714-1-AP, α-IFITM1/2/3 (F-12) Santa Cruz Biotechnology sc-374026) as indicated.

Techniques: Luciferase, Activity Assay, Expressing, Infection, Quantitative RT-PCR, Transfection, Staining

a , PLA between SARS-CoV-2 Spike and ACE2 in Calu-3 depleted of IFITM1, IFITM2 or IFITM3 and infected with genuine SARS-CoV-2. Lines represent means of n=2 (a) n=3 (b) (60-100 cells) ±SEM. b , PLA between Spike and ACE2 in Calu-3 cells depleted of IFITM2 and infected with SARS-CoV-2 virus on ice for 2 h and then incubated for 15 min at 37°C. Lines represent means of n=3 (200-300 cells) ±SEM. c , PLA assay between Spike and RAB5A in Calu-3 cells infected as in c . Lines represent means of n=2 (130-200 cells) ±SEM. DAPI (blue), nuclei. PLA signal (yellow). Scale bar, 20 µm. d , Quantification of ACE2-Spike and Spike-RAB5 alpha proximity upon SARS-CoV-2 infection.

Journal: bioRxiv

Article Title: IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition

doi: 10.1101/2020.08.18.255935

Figure Lengend Snippet: a , PLA between SARS-CoV-2 Spike and ACE2 in Calu-3 depleted of IFITM1, IFITM2 or IFITM3 and infected with genuine SARS-CoV-2. Lines represent means of n=2 (a) n=3 (b) (60-100 cells) ±SEM. b , PLA between Spike and ACE2 in Calu-3 cells depleted of IFITM2 and infected with SARS-CoV-2 virus on ice for 2 h and then incubated for 15 min at 37°C. Lines represent means of n=3 (200-300 cells) ±SEM. c , PLA assay between Spike and RAB5A in Calu-3 cells infected as in c . Lines represent means of n=2 (130-200 cells) ±SEM. DAPI (blue), nuclei. PLA signal (yellow). Scale bar, 20 µm. d , Quantification of ACE2-Spike and Spike-RAB5 alpha proximity upon SARS-CoV-2 infection.

Article Snippet: Calu-3 cells were seeded in 48-well format (peptides assays), or in 24-well format (antibodies assay), 24h later cells were treated with increasing concentrations (20 and 80µg/ml) of IFITMs derived peptides (human IFITM2 long: EEQEVAMLGVPHNPAPPMSTVIH, human IFITM2 short: QEVAMLGVPHNAPPMST-VIH, mouse IFITM2 long: EEYGVTELGEPSNSAVVRTTVIN, human IFITM3 long: EEHEVAVLGAPHNPAPPTSTVIH, scrambled IFITM2: EGESGVTTATVEVVIERNN-LPY) or blocking antibodies (15 and 30 µg/ml) (α-ACE2 AK (AC18Z), Santa Cruz Biotechnology sc-73668; α-IFITM1 Cell Signaling 13126 S, α-IFITM2 Cell Signaling 13530S, α-IFITM3 Proteintech 11714-1-AP, α-IFITM1/2/3 (F-12) Santa Cruz Biotechnology sc-374026) as indicated.

Techniques: Infection, Incubation

a , Alignment of the amino acid sequence of human IFITM1, 2 and 3. Binding sites of IFITM blocking antibodies are indicated and the region of origin of the IFITM derived peptides highlighted. b , Viral N gene RNA levels in the supernatant of Calu-3 cells treated with α-ACE2, α-IFITM1, α-IFITM2, α-IFITM3 and α-IFITM1-3 antibodies, collected 48 h post infection (MOI 0.05). Bars represent one to two independent experiments each measured in technical duplicates (mean value, ±SEM). c , RNA containing N gene sequences in the supernatant of Calu-3 cells treated with IFITM-derived peptides, collected 48 h post infection (MOI 0.05). Bars represent two to three independent experiments each measured in technical duplicates (mean value, ±SEM).

Journal: bioRxiv

Article Title: IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition

doi: 10.1101/2020.08.18.255935

Figure Lengend Snippet: a , Alignment of the amino acid sequence of human IFITM1, 2 and 3. Binding sites of IFITM blocking antibodies are indicated and the region of origin of the IFITM derived peptides highlighted. b , Viral N gene RNA levels in the supernatant of Calu-3 cells treated with α-ACE2, α-IFITM1, α-IFITM2, α-IFITM3 and α-IFITM1-3 antibodies, collected 48 h post infection (MOI 0.05). Bars represent one to two independent experiments each measured in technical duplicates (mean value, ±SEM). c , RNA containing N gene sequences in the supernatant of Calu-3 cells treated with IFITM-derived peptides, collected 48 h post infection (MOI 0.05). Bars represent two to three independent experiments each measured in technical duplicates (mean value, ±SEM).

Article Snippet: Calu-3 cells were seeded in 48-well format (peptides assays), or in 24-well format (antibodies assay), 24h later cells were treated with increasing concentrations (20 and 80µg/ml) of IFITMs derived peptides (human IFITM2 long: EEQEVAMLGVPHNPAPPMSTVIH, human IFITM2 short: QEVAMLGVPHNAPPMST-VIH, mouse IFITM2 long: EEYGVTELGEPSNSAVVRTTVIN, human IFITM3 long: EEHEVAVLGAPHNPAPPTSTVIH, scrambled IFITM2: EGESGVTTATVEVVIERNN-LPY) or blocking antibodies (15 and 30 µg/ml) (α-ACE2 AK (AC18Z), Santa Cruz Biotechnology sc-73668; α-IFITM1 Cell Signaling 13126 S, α-IFITM2 Cell Signaling 13530S, α-IFITM3 Proteintech 11714-1-AP, α-IFITM1/2/3 (F-12) Santa Cruz Biotechnology sc-374026) as indicated.

Techniques: Sequencing, Binding Assay, Blocking Assay, Derivative Assay, Infection

a , Immunofluorescence images of stem cell-derived gut organoids after stimulation with IFN-β (500 U/ml, 72 h) b , Cell-associated viral N gene RNA copy numbers in organoids treated with α-ACE2, mIFITM2 antibody blocking peptide and α-IFITM1-3 and infected with SARS-CoV-2 (MOI 0.15). c , Immunohistochemistry of gut organoids treated as in e and infected with SARS-CoV-2 (MOI 0.5). Organoids were stained with anti SARS-CoV-2 N (red), E-Cadherin (green) and DAPI (blue). Scale bar, 100 µm (left panel). SARS-CoV-2 N quantification of infected gut organoids treated as in e (right panel). d , Viral N gene RNA levels in the supernatant of SARS-CoV-2 infected cardiomyocytes (increasing MOIs as indicated), virus containing supernatants at indicated timepoints. e , Expression of IFITM1, IFITM2 and IFITM3 in cardiomyocytes infected with SARS-CoV-2. Immunoblot of whole cell lysates stained with anti-IFITM1, anti-IFITM2, anti-IFITM3 and anti-GAPDH f , Viral N gene RNA levels in the supernatant of SARS-CoV-2 infected cardiomyocytes (0.05 MOI) treated with IFITM-derived peptides, collected at indicated timepoints post infection. Bars represent two independent experiments each measured in technical duplicates (mean value, ±SEM). bql, below quantification level.

Journal: bioRxiv

Article Title: IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition

doi: 10.1101/2020.08.18.255935

Figure Lengend Snippet: a , Immunofluorescence images of stem cell-derived gut organoids after stimulation with IFN-β (500 U/ml, 72 h) b , Cell-associated viral N gene RNA copy numbers in organoids treated with α-ACE2, mIFITM2 antibody blocking peptide and α-IFITM1-3 and infected with SARS-CoV-2 (MOI 0.15). c , Immunohistochemistry of gut organoids treated as in e and infected with SARS-CoV-2 (MOI 0.5). Organoids were stained with anti SARS-CoV-2 N (red), E-Cadherin (green) and DAPI (blue). Scale bar, 100 µm (left panel). SARS-CoV-2 N quantification of infected gut organoids treated as in e (right panel). d , Viral N gene RNA levels in the supernatant of SARS-CoV-2 infected cardiomyocytes (increasing MOIs as indicated), virus containing supernatants at indicated timepoints. e , Expression of IFITM1, IFITM2 and IFITM3 in cardiomyocytes infected with SARS-CoV-2. Immunoblot of whole cell lysates stained with anti-IFITM1, anti-IFITM2, anti-IFITM3 and anti-GAPDH f , Viral N gene RNA levels in the supernatant of SARS-CoV-2 infected cardiomyocytes (0.05 MOI) treated with IFITM-derived peptides, collected at indicated timepoints post infection. Bars represent two independent experiments each measured in technical duplicates (mean value, ±SEM). bql, below quantification level.

Article Snippet: Calu-3 cells were seeded in 48-well format (peptides assays), or in 24-well format (antibodies assay), 24h later cells were treated with increasing concentrations (20 and 80µg/ml) of IFITMs derived peptides (human IFITM2 long: EEQEVAMLGVPHNPAPPMSTVIH, human IFITM2 short: QEVAMLGVPHNAPPMST-VIH, mouse IFITM2 long: EEYGVTELGEPSNSAVVRTTVIN, human IFITM3 long: EEHEVAVLGAPHNPAPPTSTVIH, scrambled IFITM2: EGESGVTTATVEVVIERNN-LPY) or blocking antibodies (15 and 30 µg/ml) (α-ACE2 AK (AC18Z), Santa Cruz Biotechnology sc-73668; α-IFITM1 Cell Signaling 13126 S, α-IFITM2 Cell Signaling 13530S, α-IFITM3 Proteintech 11714-1-AP, α-IFITM1/2/3 (F-12) Santa Cruz Biotechnology sc-374026) as indicated.

Techniques: Immunofluorescence, Derivative Assay, Blocking Assay, Infection, Immunohistochemistry, Staining, Expressing, Western Blot